1449.1000 -83.00 (-5.42%)
NSE Nov 21, 2025 15:59 PM
Volume: 145.9K
 

1449.10
-5.42%
ICICI Securities Limited
Tatva Chintan’s Q4FY23 revenue rose 26.4% YoY to Rs1.2bn as SDA revenue recovered to Rs0.5bn, up 41% YoY. However, gross profit margin dip of 400bps to 39.8% was disappointing (partly from a change in product mix) considering the company has guided for a sequential improvement in margins.
Tatva Chintan Pharma Chem Ltd. has gained 31.19% in the last 3 Months
More from Tatva Chintan Pharma Chem Ltd.
Recommended